319 related articles for article (PubMed ID: 30528798)
1. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
3. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
4. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
[TBL] [Abstract][Full Text] [Related]
6. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
Szostakowska-Rodzos M; Fabisiewicz A; Wakula M; Tabor S; Szafron L; Jagiello-Gruszfeld A; Grzybowska EA
Sci Rep; 2024 Jun; 14(1):12924. PubMed ID: 38839863
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
10. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
[No Abstract] [Full Text] [Related]
12. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
14. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
16. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
17. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
18. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
20. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
Yap YS; Leong MC; Chua YW; Loh KWJ; Lee GE; Lim EH; Dent R; Ng RCH; Lim JH; Singh G; Tan A; Guan G; Wu A; Lee YF; Bhagat AAS; Lim DW
PLoS One; 2019; 14(9):e0221305. PubMed ID: 31553731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]